NOAH Compendium

Printed from NOAH Compendium (https://www.noahcompendium.co.uk). (c) Copyright NOAH Compendium 2025. All Rights Reserved.
Date: Thursday, July 10, 2025 8:26

Description: MSD-AH
Release 3.126
Dexadreson® 2 mg/ml solution for injection
Species: Cats, Cattle, Dogs, Horses and other equidae, Pigs
Therapeutic indication: Pharmaceuticals: Anti-inflammatory preparations: Injections: Steroids
Active ingredient: Dexamethasone
Product:Dexadreson® 2 mg/ml solution for injection
Product index: Dexadreson®
Cattle - milk: 72 hours
Cattle - meat: 8 days
Pig - meat: 2 days
Withdrawal notes: Horses - meat and offal 8 days. Not authorised for use in horses producing milk for human consumption.
Incorporating:
Qualitative and quantitative composition
Each ml contains:
Active substance:
Dexamethasone (as sodium phosphate) 2 mg
Excipient:
Benzyl alcohol 15.6 mg
For the full list of excipients, see section “Pharmaceutical particulars”.
Pharmaceutical form
Clear, colourless solution for parenteral injection.
pH 7.0 - 7.8.
Clinical particulars
Target Species
Cattle, horses, pigs, dogs and cats.
Indications for use
The product may be used whenever a parenteral corticosteroid preparation giving a medium duration of activity is indicated. It can be used as an anti-inflammatory and anti-allergic agent in horses, cattle, pigs, dogs and cats and for the treatment of primary ketosis in cattle. The product can also be used to induce parturition in cattle. The product is suitable for intravenous use in the horse and is thus of particular benefit in cases needing emergency treatment.
Contraindications
Except in emergency situations the product should not be used in animals suffering from diabetes, chronic nephritis, renal disease, congestive heart failure, osteoporosis and in viral infections during the viraemic stage.
Special warnings for each target species
If the product is used for induction of parturition in cattle, then a high incidence of retained placentae may be experienced and possible subsequent metritis and/or subfertility.
Care should be taken when the product is used for the treatment of laminitis in horses, where there is the possibility that such treatment could worsen the condition. The use of the product in horses for other conditions could induce laminitis and careful observation during the treatment period should be made.
Special precautions for use
Special precautions for use in animals
Anti-inflammatory corticosteroids, such as dexamethasone, are known to exert a wide range of side effects. Whilst single high doses are generally well tolerated, they may induce severe side-effects in long term use and when esters possessing a long duration of action are administered. Dosage in medium to long term use should therefore generally be kept to the minimum necessary to control clinical signs. During a course of treatment the situation should be reviewed frequently by close veterinary supervision.
Steroids themselves, during treatment, may cause Cushingoid symptoms involving significant alteration of fat, carbohydrate, protein and mineral metabolism, e.g., redistribution of body fat, muscle weakness and wastage and osteoporosis may result. During therapy effective doses suppress the hypothalamo-pituitreal-adrenal axis. Following cessation of treatment, signs of adrenal insufficiency extending to adrenocortical atrophy can arise and this may render the animal unable to deal adequately with stressful situations. Consideration should therefore be given to means of minimising problems of adrenal insufficiency following the withdrawal of treatment, e.g., dosing to coincide with the time of the endogenous cortisol peak (i.e., in the morning with regard to dogs and the evening for cats) and a gradual reduction of dosage (for further discussion see standard texts).
Corticosteroids may delay wound healing and the immunosuppressive effect can weaken the immune system or worsen pre-existing infections. In the presence of bacterial infection, antibacterial drug cover is usually required when steroids are used.
In the presence of viral infections, steroids may worsen or hasten the progress of the disease.
Gastrointestinal ulceration has been reported in animals treated with corticosteroids and gastrointestinal tract ulceration may be exacerbated by steroids in patients given non-steroidal anti-inflammatory drugs and in animals with spinal cord trauma.
Operator warnings
The veterinary medicinal product can cause allergic reactions. People with known hypersensitivity to the active substance or to any of the excipients should avoid contact with the veterinary medicinal product.
Care should be taken to avoid accidental self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
To avoid the risk of self-injection, pregnant women should not handle the veterinary medicinal product.
Avoid contact with skin and eyes. In the event of accidental eye or skin contact, wash/irrigate the area with clean running water. Seek medical attention if irritation persists.
Wash hands after use.
Adverse Reactions
Cattle, horses, pigs, dogs and cats:
Very rare (<1 animal / 10,000 animals treated, including isolated reports):
Polyuria1
Polydipsia1
Polyphagia1
Hepatomegaly
Elevated liver enzymes
Other blood disorder (retention of water, sodium and hypokalemia)2
Cutaneous calcinosis
Delayed healing Hypersensitivity
1 Particularly during the early stages of therapy.
2 During long term use.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy or lactation
Apart from the use to induce parturition in cattle, corticosteroids are not recommended for use in pregnant animals. Administration in early pregnancy is known to have caused foetal abnormalities in laboratory animals. Administration in late pregnancy may cause early parturition or abortion.
Use of the product in lactating cows may cause a reduction in milk yield.
Interactions
Because corticosteroids can reduce the immune response to vaccination, the product should not be used in combination with vaccines.
Amounts to be administered and administration route
Cattle, pigs, dogs and cats: Intramuscular use.
Horses: Intravenous, intramuscular or intra-articular use.
Normal aseptic technique should be observed.
For the treatment of inflammatory or allergic conditions: The following average doses are advised. However, the actual dose used should be determined by the severity of the signs and the length of time for which they have been present.
Species
Dosage
Horses, cattle, pigs
1.5 ml/50 kg
Dogs, cats
0.5 ml/10 kg
For the treatment of primary ketosis in cattle: A dose of 5-10 ml given by intramuscular injection is advocated dependent on the size of the cow and the duration of the signs. Care should be taken not to overdose Channel Island breeds. Larger doses will be required if the signs have been present for some time or if relapsed animals are being treated.
For the induction of parturition: To avoid foetal oversize and mammary oedema in cattle.
A single intramuscular injection of 10 ml after day 260 of pregnancy.
Parturition will normally occur within 48-72 hours.
For the treatment of arthritis, bursitis or tenosynovitis: By intra-articular injection in the horse.
Dose 1 - 5 ml.
These quantities are not specific and are quoted purely as a guide. Injections into joint spaces or bursae should be preceded by the removal of an equivalent volume of synovial fluid. Strict asepsis is essential.
To ensure a correct dosage, body weight should be determined as accurately as possible.
To measure small volumes of less than 1 ml a suitably graduated syringe should be used to ensure accurate administration of the correct dose.
Overdose
See “Adverse Reactions:” above
Withdrawal periods
Cattle: Meat and offal: 8 days, Milk: 72 hours
Pigs: Meat and offal: 2 days
Horses: Meat and offal: 8 days
Not authorised for use in horses producing milk for human consumption.
Pharmacological particulars
ATCvet code: QH02AB02.
Pharmacodynamic properties
This preparation contains the sodium phosphate ester of dexamethasone, a fluoro-methyl derivative of prednisolone, which is a potent glucocorticoid with minimal mineralocorticoid activity. Dexamethasone has ten to twenty times the anti-inflammatory activity of prednisolone.
Following intramuscular injection this soluble ester of dexamethasone is rapidly absorbed and hydrolysed to the parent alcohol giving a prompt response which is maintained for approximately 48 hours.
Pharmacokinetic particulars
This veterinary medicinal product is a short acting dexamethasone preparation with a rapid onset of activity. It contains the disodium phosphate ester of dexamethasone. After extravascular (intramuscular, subcutaneous, intraarticular) administration, the ester is rapidly resorbed from the injection site followed by immediate hydrolysation into the parent compound, dexamethasone. Absorption of dexamethasone is rapid. The time to reach maximum plasma concentrations (Cmax) of dexamethasone in cattle, horses, pigs and dogs is within 20 minutes after intramuscular administration. Bioavailability following intramuscular. administration (compared to intravenous. administration) is high in all species. Elimination half-life after intravenous administration in horses is 3.5 hours. After intramuscular administration, apparent elimination half-life has been shown to range between 1 and 20 hours according to the species.
Pharmaceutical particulars
Excipients
Benzyl alcohol, sodium chloride, sodium citrate, citric acid– (for pH adjustment), sodium hydroxide – (for pH adjustment) and water for injections.
Major incompatibilities
Do not mix the product with other veterinary medicinal products.
Shelf-life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Shelf life after first opening the immediate packaging: 28 days.
Special precautions for storage
Do not store above 25 °C.
Protect from light.
Immediate packaging
50 ml clear, Type I, glass vials with a halogenobutyl rubber stopper, closed with a colour coded aluminium cap.
Pack size:
Cardboard box containing a 50 ml vial.
Disposal
Medicines should not be disposed of via wastewater.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.
Marketing Authorisation Holder (if different from distributor)
Intervet International B.V., represented by MSD Animal Health UK Limited.
Marketing Authorisation Number
UK: Vm 06376/4085
Significant changes
Date of the first authorisation or date of renewal
4 November 1994
Date of revision of the text
April 2025.
Any other information
For animal treatment only. Keep out of the sight and reach of children.
Legal category
Legal category: POM-V
GTIN
GTIN description:Dexadreson 1x50ml:
GTIN:8713184005977